Status:

RECRUITING

Circulating Tumor DNA in Soft Tissue Sarcoma

Lead Sponsor:

University Health Network, Toronto

Collaborating Sponsors:

Mount Sinai Hospital, Canada

The Hospital for Sick Children

Conditions:

Soft Tissue Sarcoma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DN...

Detailed Description

Researchers are continually looking for ways to understand the biology of cancer such as sarcoma, and ways to improve cancer care and patient outcome. Research has shown that changes in some genes an...

Eligibility Criteria

Inclusion

  • Patients must have histologically confirmed high-risk extremity or retroperitoneal liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sarcoma.
  • Patients must have archival tissue from the diagnostic biopsy available.
  • Deemed appropriate for preoperative or postoperative radiotherapy and curative surgery following patient assessment by radiation oncologist and surgical oncologist.
  • Age 18 years or older.
  • Eastern Cooperative Group (ECOG) performance status ≤ 2
  • Ability to understand and willing to sign a written informed consent document and comply with study requirements.

Exclusion

  • Patients with benign histology
  • Patients with prior malignancy within previous 5 years or concurrent malignancy other than adequately treated basal cell carcinoma of skin or carcinoma in-situ of cervix.
  • Patients with planned neo-adjuvant chemotherapy.
  • Patients with regional nodal disease or unequivocal metastases
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Key Trial Info

Start Date :

January 17 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 17 2025

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT03818412

Start Date

January 17 2019

End Date

January 17 2025

Last Update

March 22 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Princess Margaret Cancer Centre

Toronto, Ontario, Canada, M5G 2M9